Gabriele Grassi

List of Publications by Year
in descending order

122	3,298	156536	214428
papers	citations	32 h-index	50 g-index

126	126	126	5252
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Trabecular bone porosity and pore size distribution in osteoporotic patients â€“ A low field nuclear magnetic resonance and microcomputed tomography investigation. Journal of the Mechanical Behavior of Biomedical Materials, 2022, 125, 104933.	1.5	15
2	Effects of autophagy inhibition by chloroquine on hepatic stellate cell activation in CCl₄â€induced acute liver injury mouse model. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 216-224.	1.4	6
3	Effect of chest physiotherapy on cystic fibrosis sputum nanostructure: an experimental and theoretical approach. Drug Delivery and Translational Research, 2022, 12, 1943-1958.	3.0	3
4	An Overview of siRNA Delivery Strategies for Urological Cancers. Pharmaceutics, 2022, 14, 718.	2.0	5
5	High eEF1A1 Protein Levels Mark Aggressive Prostate Cancers and the In Vitro Targeting of eEF1A1 Reveals the eEF1A1â€“Actin Complex as a New Potential Target for Therapy. International Journal of Molecular Sciences, 2022, 23, 4143.	1.8	3
6	5-Azacytidine Downregulates the Proliferation and Migration of Hepatocellular Carcinoma Cells In Vitro and In Vivo by Targeting miR-139-5p/ROCK2 Pathway. Cancers, 2022, 14, 1630.	1.7	8
7	Targeted delivery of siRNAs against hepatocellular carcinoma-related genes by a galactosylated polyaspartamide copolymer. Journal of Controlled Release, 2021, 330, 1132-1151.	4.8	27
8	YAPâ€“TEAD1 control of cytoskeleton dynamics and intracellular tension guides human pluripotent stem cell mesoderm specification. Cell Death and Differentiation, 2021, 28, 1193-1207.	5.0	33
9	Xenograft Zebrafish Models for the Development of Novel Anti-Hepatocellular Carcinoma Molecules. Pharmaceuticals, 2021, 14, 803.	1.7	3
10	Combined use of rheology and portable low-field NMR in cystic fibrosis patients. Respiratory Medicine, 2021, 189, 106623.	1.3	7
11	Optimization of the isolation procedure and culturing conditions for hepatic stellate cells obtained from mouse. Bioscience Reports, 2021, 41, .	1.1	12
12	Thermal gelation modeling of a pluronicâ€alginate blend following coronary angioplasty. Journal of Applied Polymer Science, 2020, 137, 48539.	1.3	2
13	Effects of eEF1A1 targeting by aptamer/siRNA in chronic lymphocytic leukaemia cells. International Journal of Pharmaceutics, 2020, 574, 118895.	2.6	12
14	Use of low field nuclear magnetic resonance to monitor lung inflammation and the amount of pathological components in the sputum of cystic fibrosis patients. Magnetic Resonance in Medicine, 2020, 84, 427-436.	1.9	5
15	Directâ€acting antiviral agents for hepatitis C virusâ€mixed cryoglobulinaemia: dissociated virological and haematological responses. British Journal of Haematology, 2020, 191, 775-783.	1.2	20
16	Extra-Intestinal Effects of C. difficile Toxin A and B: An In Vivo Study Using the Zebrafish Embryo Model. Cells, 2020, 9, 2575.	1.8	7
17	The Extracellular Matrix Influences Ovarian Carcinoma Cellsâ€™ Sensitivity to Cisplatinum: A First Step towards Personalized Medicine. Cancers, 2020, 12, 1175.	1.7	9
18	Drug Repurposing in Human Cancers. Current Medicinal Chemistry, 2020, 27, 7213-7213.	1.2	3

#	Article	IF	Citations
19	Drugs Repurposing in High-Grade Serous Ovarian Cancer. Current Medicinal Chemistry, 2020, 27, 7222-7233.	1.2	5
20	Dissolution of an ensemble of differently shaped poly-dispersed drug particles undergoing solubility reduction: mathematical modelling. ADMET and DMPK, 2020, 8, 297-313.	1.1	3
21	Strategies for Delivery of siRNAs to Ovarian Cancer Cells. Pharmaceutics, 2019, 11, 547.	2.0	18
22	A rapid and specific method to simultaneously quantify eukaryotic elongation factor 1A1 and A2 protein levels in cancer cells. Journal of Pharmaceutical and Biomedical Analysis, 2019, 176, 112814.	1.4	4
23	In vitro metabolic zonation through oxygen gradient on a chip. Scientific Reports, 2019, 9, 13557.	1.6	52
24	Virtual screening identifies a PIN1 inhibitor with possible antiovarian cancer effects. Journal of Cellular Physiology, 2019, 234, 15708-15716.	2.0	19
25	Antibacterial drug release from a biphasic gel system: Mathematical modelling. International Journal of Pharmaceutics, 2019, 559, 373-381.	2.6	7
26	The remarkable three-dimensional network structure of bacterial cellulose for tissue engineering applications. International Journal of Pharmaceutics, 2019, 566, 631-640.	2.6	59
27	Theoretical Importance of PVP-Alginate Hydrogels Structure on Drug Release Kinetics. Gels, 2019, 5, 22.	2.1	5
28	E2F1 as a molecular drug target in ovarian cancer. Expert Opinion on Therapeutic Targets, 2019, 23, 161-164.	1.5	26
29	Mathematical modeling of L-(+)-ascorbic acid delivery from pectin films (packaging) to agar hydrogels (food). Journal of Food Engineering, 2018, 234, 73-81.	2.7	15
30	A novel approach based on lowâ€field NMR for the detection of the pathological components of sputum in cystic fibrosis patients. Magnetic Resonance in Medicine, 2018, 79, 2323-2331.	1.9	14
31	Combined Used of Rheology and LF-NMR for the Characterization of PVP-Alginates Gels Containing Liposomes. Pharmaceutical Research, 2018, 35, 171.	1.7	14
32	Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases. Diseases (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.0	26
33	Polymer-Mediated Delivery of siRNAs to Hepatocellular Carcinoma: Variables Affecting Specificity and Effectiveness. Molecules, 2018, 23, 777.	1.7	18
34	Drug delivery from polymeric matrices. Computer Aided Chemical Engineering, 2018, 42, 325-356.	0.3	4
35	Effects of Hypoxia and Bed Rest on Markers of Cardiometabolic Risk: Compensatory Changes in Circulating TRAIL and Glutathione Redox Capacity. Frontiers in Physiology, 2018, 9, 1000.	1.3	11
36	Use of low-field NMR for the characterization of gels and biological tissues. ADMET and DMPK, 2018, 6, 34.	1.1	22

#	Article	IF	Citations
37	Galactosylated polyaspartamide copolymers for siRNA targeted delivery to hepatocellular carcinoma cells. International Journal of Pharmaceutics, 2017, 525, 397-406.	2.6	23
38	Dissecting the role of the elongation factor 1A isoforms in hepatocellular carcinoma cells by liposome-mediated delivery of siRNAs. International Journal of Pharmaceutics, 2017, 525, 367-376.	2.6	17
39	Engineering approaches in siRNA delivery. International Journal of Pharmaceutics, 2017, 525, 343-358.	2.6	21
40	Characterization of PLLA scaffolds for biomedical applications. International Journal of Polymeric Materials and Polymeric Biomaterials, 2017, 66, 469-477.	1.8	2
41	In vitro and ex vivo delivery of tailored siRNA-nanoliposomes for E2F1 silencing as a potential therapy for colorectal cancer. International Journal of Pharmaceutics, 2017, 525, 377-387.	2.6	23
42	Strategies to optimize siRNA delivery to hepatocellular carcinoma cells. Expert Opinion on Drug Delivery, 2017, 14, 797-810.	2.4	25
43	Recent advances in smart biotechnology: Hydrogels and nanocarriers for tailored bioactive molecules depot. Advances in Colloid and Interface Science, 2017, 249, 163-180.	7.0	44
44	Modulating carbohydrate-based hydrogels as viscoelastic lubricant substitute for articular cartilages. International Journal of Biological Macromolecules, 2017, 102, 796-804.	3.6	15
45	Exploring the Shape Influence on Melting Temperature, Enthalpy, and Solubility of Organic Drug Nanocrystals by a Thermodynamic Model. Crystal Growth and Design, 2017, 17, 4072-4083.	1.4	18
46	Mathematical Modeling of Drug Release from Natural Polysaccharides Based Matrices. Natural Product Communications, 2017, 12, 1934578X1701200.	0.2	4
47	Potential Applications of Nanocellulose-Containing Materials in the Biomedical Field. Materials, 2017, 10, 977.	1.3	113
48	Keratin14 mRNA expression in human pneumocytes during quiescence, repair and disease. PLoS ONE, 2017, 12, e0172130.	1.1	8
49	Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals. Anti-Cancer Agents in Medicinal Chemistry, 2016, 16, 1385-1402.	0.9	20
50	A nanoporous surface is essential for glomerular podocyte differentiation in three-dimensional culture. International Journal of Nanomedicine, 2016, Volume 11, 4957-4973.	3.3	11
51	In situ coronary stent paving by <scp>P</scp>luronic <scp>F</scp>127â€“alginate gel blends: Formulation and erosion tests. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2016, 104, 1013-1022.	1.6	9
52	Thermoâ€responsive hydrogels from celluloseâ€based polyelectrolytes and catanionic vesicles for biomedical application. Journal of Biomedical Materials Research - Part A, 2016, 104, 1668-1679.	2.1	15
53	Rapid and cost-effective xenograft hepatocellular carcinoma model in Zebrafish for drug testing. International Journal of Pharmaceutics, 2016, 515, 583-591.	2.6	21
54	Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effects. International Journal of Pharmaceutics, 2016, 506, 268-279.	2.6	22

#	Article	IF	Citations
55	Growth Rate of Small Abdominal Aortic Aneurysms and Genetic Polymorphisms of Matrix MetalloProteases-1, -3, and -9. International Journal of Angiology, 2016, 25, 093-098.	0.2	9
56	Vitamin delivery: Carriers based on nanoliposomes produced via ultrasonic irradiation. LWT - Food Science and Technology, 2016, 69, 9-16.	2.5	73
57	The Role of the Transcription Factor E2F1 in Hepatocellular Carcinoma. Current Drug Delivery, 2016, 13, 1-1.	0.8	42
58	Chemical Engineering in the â€œBIOâ€•world. Current Drug Delivery, 2016, 13, 1-1.	0.8	4
59	Polysaccharides for the Delivery of Antitumor Drugs. Materials, 2015, 8, 2569-2615.	1.3	110
60	Development of a simple, biocompatible and cost-effective Inulin-Diethylenetriamine based siRNA delivery system. European Journal of Pharmaceutical Sciences, 2015, 75, 60-71.	1.9	40
61	Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells. Biochimie, 2015, 112, 85-95.	1.3	29
62	Liposomes as siRNA Delivery Vectors. Current Drug Metabolism, 2015, 15, 882-892.	0.7	46
63	Novel Lipid and Polymeric Materials as Delivery Systems for Nucleic Acid Based Drugs. Current Drug Metabolism, 2015, 16, 427-452.	0.7	26
64	Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 8994.	1.4	22
65	Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials. World Journal of Gastroenterology, 2014, 20, 1268.	1.4	68
66	Targeting pleiotropic signaling pathways to control adult cardiac stem cell fate and function. Frontiers in Physiology, 2014, 5, 219.	1.3	4
67	Modeling of the reticulation kinetics of alginate/pluronic blends for biomedical applications. Materials Science and Engineering C, 2014, 37, 327-331.	3.8	17
68	Physical characterization of alginateâ€“Pluronic F127 gel for endoluminal NABDs delivery. Soft Matter, 2014, 10, 729-737.	1.2	39
69	Topological characterization of a bacterial celluloseâ€“acrylic acid polymeric matrix. European Journal of Pharmaceutical Sciences, 2014, 62, 326-333.	1.9	15
70	Application of mathematical modeling in sustained release delivery systems. Expert Opinion on Drug Delivery, 2014, 11, 1299-1321.	2.4	42
71	Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines. World Journal of Gastroenterology, 2014, 20, 795.	1.4	30
72	A physiologically oriented mathematical model for the description of in vivo drug release and absorption. ADMET and DMPK, 2014, 2, .	1.1	9

#	Article	IF	Citations
73	Can TIE-2 expressing monocytes represent a novel marker for hepatocellular carcinoma?. Hepatobiliary Surgery and Nutrition, 2014, 3, 175-8.	0.7	2
74	Reduction of melting temperature and enthalpy of drug crystals: Theoretical aspects. European Journal of Pharmaceutical Sciences, 2013, 50, 17-28.	1.9	29
75	First-in-human trial of Dz13 for nodular basal-cell carcinoma. Lancet, The, 2013, 381, 1797-1798.	6.3	7
76	The more basic isoform of eEF1A relates to tumour cell phenotype and is modulated by hyperâ€proliferative/differentiating stimuli in normal lymphocytes and CCRFâ€CEM Tâ€lymphoblasts. Hematological Oncology, 2013, 31, 110-116.	0.8	9
77	Editorial (Hot Topic: Improving Drug Efficacy and Specificity by Innovative Drug Delivery Approaches). Current Medicinal Chemistry, 2013, 20, 3427-3428.	1.2	0
78	Therapeutic Potential of Nucleic Acid-Based Drugs in Coronary Hyper- Proliferative Vascular Diseases. Current Medicinal Chemistry, 2013, 20, 3515-3538.	1.2	21
79	Aptamers as Targeting Delivery Devices or Anti-cancer Drugs for Fighting Tumors. Current Drug Metabolism, 2013, 14, 565-582.	0.7	24
80	Oral anticoagulation and VKORC1 polymorphism in patients with a mechanical heart prosthesis: a 6-year follow-up. Journal of Thrombosis and Thrombolysis, 2012, 34, 506-512.	1.0	10
81	Effects of E2F1â€“cyclin E1â€“E2 circuit down regulation in hepatocellular carcinoma cells. Digestive and Liver Disease, 2011, 43, 1006-1014.	0.4	42
82	Two-dimensional enzyme diffusion in laterally confined DNA monolayers. Nature Communications, 2011, 2, 297.	5.8	23
83	Features of vulnerable plaques and clinical outcome of UA/NSTEMI: Relationship with matrix metalloproteinase functional polymorphisms. Atherosclerosis, 2011, 215, 153-159.	0.4	20
84	Improving siRNA Bio-Distribution and Minimizing Side Effects. Current Drug Metabolism, 2011, 12, 11-23.	0.7	48
85	Mathematical modeling of simultaneous drug release and in vivo absorption. International Journal of Pharmaceutics, 2011, 418, 130-141.	2.6	55
86	Proliferation of human primary vascular smooth muscle cells depends on serum response factor. European Journal of Cell Biology, 2010, 89, 216-224.	1.6	41
87	Simultaneous Release and ADME Processes of Poorly Water-Soluble Drugs: Mathematical Modeling. Molecular Pharmaceutics, 2010, 7, 1488-1497.	2.3	15
88	Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6. Biochimie, 2010, 92, 455-463.	1.3	34
89	Role of E2F1-Cyclin E1-Cyclin E2 Circuit in Human Coronary Smooth Muscle Cell Proliferation and Therapeutic Potential of Its Downregulation by siRNAs. Molecular Medicine, 2009, 15, 297-306.	1.9	39
90	Novel design of drug delivery in stented arteries: A numerical comparative study. Mathematical Biosciences and Engineering, 2009, 6, 493-508.	1.0	27

#	Article	IF	Citations
91	Short Term Effects of Doxycycline on Matrix Metalloproteinases 2 and 9. Cardiovascular Drugs and Therapy, 2009, 23, 153-159.	1.3	19
92	Synthesis and Spontaneous Polymerization of Oligo(ethylene glycol)-Conjugated Benzofulvene Macromonomers. A Polymer Brush Forming a Physical Hydrogel. Macromolecules, 2009, 42, 2368-2378.	2.2	35
93	Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie, 2009, 91, 373-382.	1.3	61
94	Structural Characterization of Calcium Alginate Matrices by Means of Mechanical and Release Tests. Molecules, 2009, 14, 3003-3017.	1.7	46
95	Targeting of protease 2A genome by single and multiple siRNAS as a strategy to impair CVB3 life cycle in permissive HeLa cells. Methods and Findings in Experimental and Clinical Pharmacology, 2009, 31, 63.	0.8	8
96	Connective tissue growth factor: a crucial cytokine-mediating cardiac fibrosis in ongoing enterovirus myocarditis. Journal of Molecular Medicine, 2008, 86, 49-60.	1.7	75
97	Inhibitory effects of fenofibrate on apoptosis and cell proliferation in human endothelial cells in high glucose. Journal of Molecular Medicine, 2008, 86, 185-195.	1.7	38
98	Alcohol reduces MMP-2 in humans and isolated smooth muscle cells. Alcohol, 2008, 42, 389-395.	0.8	17
99	Prostate Tumor-Inducing Gene-1 Analysis in Human Prostate Cancer Cells and Tissue in Relation toMycoplasmaInfection. Cancer Investigation, 2008, 26, 800-808.	0.6	4
100	Effects of Various Promoter Derived Sequences on the Cleavage Kinetic of an Hammerhead Ribozyme Directed Against Cyclin E1 mRNA. Drug Metabolism Letters, 2007, 1, 218-225.	0.5	2
101	Decreased IL-10 mRNA expression in patients with advanced renal failure undergoing conservative treatment. Cytokine, 2007, 40, 71-74.	1.4	8
102	Vascular Sources of Oxidative Stress: Implications for Uremia-Related Cardiovascular Disease. , 2007, 17, 53-56.		4
103	Overexpression of the elongation factor 1A1 relates to muscle proteolysis and proapoptotic p66(ShcA) gene transcription in hypercatabolic trauma patients. Metabolism: Clinical and Experimental, 2007, 56, 1629-1634.	1.5	15
104	Relation between the plasma levels of LDL-cholesterol and the expression of the early marker of inflammation long pentraxin PTX3 and the stress response gene p66(ShcA) in pacemaker-implanted patients. Clinical and Experimental Medicine, 2007, 7, 16-23.	1.9	42
105	Interaction of G-rich GT oligonucleotides with nuclear-associated eEF1A is correlated with their antiproliferative effect in haematopoietic human cancer cell lines. FEBS Journal, 2006, 273, 1350-1361.	2.2	29
106	Comparison between recombinant baculo- and adenoviral-vectors as transfer system in cardiovascular cells. Archives of Virology, 2006, 151, 255-271.	0.9	20
107	Association of interferon-Î³ +874A polymorphism with reduced long-term inflammatory response in haemodialysis patients. Nephrology Dialysis Transplantation, 2006, 21, 1317-1322.	0.4	27
108	MMP-9 Microsatellite Polymorphism and Susceptibility to Carotid Arteries Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1330-1336.	1.1	39

#	Article	IF	Citations
109	Hammerhead ribozymes targeted against cyclin E and E2F1 cooperate to down-regulate coronary smooth muscle cell proliferation. Journal of Gene Medicine, 2005, 7, 1223-1234.	1.4	32
110	Mathematical Modelling and Controlled Drug Delivery: Matrix Systems. Current Drug Delivery, 2005, 2, 97-116.	0.8	300
111	The impact of inflammation on metabolic regulation in chronic kidney disease: A review. , 2005, 15, 121-124.		10
112	Temperature-Sensitive Hydrogels. American Journal of Drug Delivery, 2005, 3, 239-251.	0.6	44
113	Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases. Current Pharmaceutical Biotechnology, 2004, 5, 369-386.	0.9	28
114	Light Regulates the Cell Cycle in Zebrafish. Current Biology, 2003, 13, 2051-2057.	1.8	163
115	Inhibitors of DNA methylation and histone deacetylation activate cytomegalovirus promoter-controlled reporter gene expression in human glioblastoma cell line U87. Carcinogenesis, 2003, 24, 1625-1635.	1.3	69
116	Determination of hammerhead ribozyme kinetic constants at high molar ratio ribozyme-substrate. Journal of Mathematical Biology, 2002, 45, 261-277.	0.8	3
117	Selection and Characterization of Active Hammerhead Ribozymes Targeted Against Cyclin E and E2F1 Full-Length mRNA. Oligonucleotides, 2001, 11, 271-287.	4.4	9
118	Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease. Hepatology, 1998, 27, 1678-1686.	3.6	50
119	Functional Reconstitution of Oxidase Activity in X-Linked Chronic Granulomatous Disease by Retrovirus-Mediated Gene Transfer. Experimental Cell Research, 1996, 225, 257-267.	1.2	7
120	Ribozymes: Structure, Function and Potential Therapy for Dominant Genetic Disorders. Annals of Medicine, 1996, 28, 499-510.	1.5	44
121	Quantitative analysis of hepatitis C virus RNA in liver biopsies by competitive reverse transcription and polymerase chain reaction. Journal of Hepatology, 1995, 23, 403-411.	1.8	29
122	A rapid procedure for the quantitation of low abundance RNAs by competitive reverse transcription-polymerase chain reaction. Nucleic Acids Research, 1994, 22, 4547-4549.	6.5	36